DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Market Access Considerations for COPD and Asthma

By: Colleen Albacker, Ph.D. | Andrea Kravit | Elena Kozhemyakina, Ph.D. | Kristine Mackin, Ph.D. | Eun-Jin Yang, Ph.D. | Qinghui Yu, Ph.D.

Published: October 2016

Payers’ Increasing Role in Shaping the U.S. and EU5 Market Access Landscapes

COPD and asthma are highly prevalent respiratory conditions, together affecting over 100 million people in the United States and the five largest European mar- kets (France, Germany, Italy, Spain, and the United Kingdom). The chronic nature of these diseases means that a significant portion of these patient populations require lifelong treatment to manage their symptoms, and combined with the high prevalence of COPD and asthma, ensures that these diseases will continue to exert a substantial financial burden on national healthcare systems and payers. Furthermore, while some market events such as the launch of inhaled generic fixed-dose combinations will help to mitigate costs, other events such as the launch of novel, premium-priced biologic therapies targeted at severe refractory asthma could place additional pressure on healthcare systems. Thus, unsurprisingly, the behavior of payers—as they seek to control costs associated with these diseases—is anticipated to play an increasingly influential role in shaping the market access land- scape for both COPD and asthma in the United States and EU5.